

令和 6(2024)年度 研究成果の刊行に関する一覧表 【書籍】

著者氏名		論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	保坂哲也	B 型慢性肝炎の治療（核酸 アナログ）	三田英治 平松直樹	必ず役立つ！肝炎 診療バイブル（改 訂 6 版）	メディカ出 版	大阪	2024	129-138	○
2)	保坂哲也	・ 肝炎ウイルスマーカー ・ B 型肝炎に対する治療薬 ・ B 型慢性肝炎（病態）	日本肝臓学会	肝臓専門医テキス ト（改訂第 4 版）	南江堂	東京	2024	91-93 186-191 308-312	○
3)	清水雅仁		一般財団法人 日本肝臓学会	肝臓専門医テキス ト 改訂第 4 版	南江堂	東京	2024		○

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Nishimura T, Tada T, <u>Akita T</u> , Kondo R, Suzuki Y, Imajo K, Kokubu S, Abe T, Kuroda H, Hirooka M, Hiasa Y, Nogami A, Nakajima A, Ogawa S, <u>Toyoda H</u> , Oeda S, Takahashi H, Eguchi Y, Sugimoto K, Yano H, <u>Tanaka J</u> , Moriyasu F, Kage M, Kumada T, Iijima H	Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study	Journal of Gastroenterology			in press	○
2)	Kaneyasu Y, Fujiwara H, <u>Akita T</u> , <u>Tanaka J</u> , Shibata Y, Nakagawa T, Koh I, Hirata E, Hyodo M, Miyamoto T, Murakami Y, Nishibuchi I, Imano N, Nagata Y, Kudo Y	Suppressive effect of vitamin K2 (menatetrenone) against bone mineral density loss after radiotherapy in uterine cancer patients	Japanese Journal of Radiology			in press	
3)	Tada T, Kumada T, <u>Toyoda H</u> , Yasuda S, Koshiyama Y, <u>Akita T</u> , Kodama Y, <u>Tanaka J</u>	Association of liver fibrosis progression with non-liver-related mortality in metabolic dysfunction-associated steatotic liver disease	Hepatology Research			in press	
4)	Nagata T, Chimed-Ochir O, Yumiya Y, <u>Tanaka J</u> , Kuwabara M, Kitahara K, Ohge H, Kubo T	Effect of individual preventive practices on COVID-19 infection: an analysis of big data collected at PCR testing centers in Hiroshima, Japan	Virus Research	25(1)	681	2025	
5)	Ota Y, Yumiya Y, Chimed-Ochir O, Hasegawa A, Yoshida T, Nagata T, <u>Tanaka J</u> , Ohge H, Kuwabara M, Kubo T	Characteristics of patients with COVID-19 and smell and/or taste disorders depending on different virus strains: a cross-sectional study in Hiroshima, Japan	BMJ Open	15(2)	e088377	2025	
6)	Ohira M, Imaoka Y, Sato K, Imaoka K, Bekki T, Yano T, Nakano R, Sakai H, Kuroda S, Tahara H, Ide K, Kobayashi T, Tanaka Y, <u>Tanaka J</u> , Ohdan H	A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation	PLoS ONE	20(1)		2025	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
7)	Nomura N, Matsumoto H, Asano K, Hayashi Y, Yokoyama A, Nishimura Y, Hashimoto N, Sakagami T, Fukunaga K, Hizawa N, Yamasaki A, Nagase H, Hattori N, Kondo M, Harada N, Sugiura H, Miki M, Kimura T, Toyoshima M, Matsuno O, Koh H, Kita T, Tomioka H, Tomii K, Ohnishi H, Takata S, Tobino K, Imokawa S, Sunadome H, Nagasaki T, Oguma T, Tanabe N, Hirai T, Ikeda M, Okamura K, Terada-Hirashima J, Hojo M, Isogai S, Imaizumi K, Horiguchi T, Hirano R, Fujita M, Fujisawa T, Suda T, Takaki Y, Higaki N, Miyamoto S, Nakashima T, Iwamoto H, Mikami K, Minami T, Takahashi R, Kijima T, Hoshino M, Tsuji T, Hiraoka N, Ikeue T, Sugita T, Kunichika N, Tomari S, Okochi Y, Mato N, Hagiwara K, Dobashi K, Taooka Y, Machida K, Inoue H, Tanosaki T, Masaki K, Sano A, Iwanaga T, Higashimoto Y, Tohda Y, Matsumoto M, Takatsuki K, Nagata K, Tachikawa R, Kaneko M, Nagano T, Yamane M, Yoshida C, Seto Y, Kaneko Y, Takayama K, Terada S, Nishi K, Tajiri T, Niimi A, Nakamura S, Wakahara K, Ito T, Nakano T.F, Yamashita T, Seri Y, Mizumori Y, Tsukamoto H, Kagami R, Nakahara Y, Kawamura T, Ishii Y, Hidaka K, Kadowaki T, Minakuchi M, Tsuboi T, Tamaki S, Matsuki T, Kida H, Tomita K, Abe T, Shindoh J, Taniguchi A, Miyahara N, Azuma M, Kataoka M, Ogawa H, Matsumoto T, Aihara K, Nakagome K, Nagata M, Miyajima S, Hashimoto K, Shiota T, Yamaguchi M, Nakano Y, Otsuka K, Yasuo M, Hanaoka M, Yamada T, Shirai T, Iwasaki Y, Mineshita M, Tsuburai T, Komase Y, Hasegawa K, Kita H, Murakami K, Ichinose M, Kutsuzawa T, <u>Tanaka J</u> , Kono Y, Abe S, Nakamura M, Orimo M, Tagaya E, Matsuda T, Harada T, Taniguchi H, Iijima H, Kawabata H, Yatera K, Masuko H, Morishima Y, Nakanishi M, Yamamoto N, Inoue S, Hamada K, Yamaji Y, Hirano T, Matsunaga K, Sato Y	Refractory phenotype of Aspergillus-sensitized asthma with bronchiectasis and allergic bronchopulmonary aspergillosis	Journal of Allergy and Clinical Immunology: Global	4(1)		2025	
8)	Gotoh T, Kumada T, Ogawa S, Niwa F, <u>Toyoda H</u> , Hirooka M, Koizumi Y, Hiasa Y, <u>Akita T</u> , <u>Tanaka J</u> , Shimizu M	Comparison Between Attenuation Measurement and the Controlled Attenuation Parameter for the Assessment of Hepatic Steatosis Based on MRI Images	Liver International	45(1)		2025	○
9)	Mirzaev U.K, Yoshinaga Y, Baynazarov M, Ouoba S, Ko K, Phyo Z, Chhoung C, Akuffo G.A, <u>Sugiyama A</u> , <u>Akita T</u> , Takahashi K, Fukuma S, <u>Tanaka J</u>	Diagnostic accuracy of hepatitis E virus antibody tests: A comprehensive meta-analysis	Hepatology Research			in press	○
10)	Phyo Z, Tanaka S, <u>Sugiyama A</u> , Ko K, Takahashi K, Mirzaev U.K, Akuffo G.A, Chhoung C, <u>Akita T</u> , Kozuki M, Sakamori R, <u>Tanaka J</u>	Unveiling the dynamics of hepatitis C virus transmission among injection drug users and men who have sex with men: A comprehensive study in Japan	Hepatology Research			in press	○
11)	Yumiya Y, Kawanishi K, Chimed-Ochir O, Kishita E, <u>Sugiyama A</u> , <u>Tanaka J</u> , Kubo T	Effectiveness of COVID-19 mRNA vaccine in preventing infection against Omicron strain: Findings from the Hiroshima Prefecture COVID-19 version J-SPEED for PCR center	PLOS Global Public Health	4(4)	e0003071	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	Akita T, Kurisu A, Masumoto F, Bunthen E, Sugiyama A, Kawaoka T, Imamura M, Aikata H, Seike M, Akuta N, Kumada T, Karino Y, Chayama K, Tanaka I	Health-related quality of life after sustained virological response to treatment for hepatitis C	Hiroshima Journal of Medical Sciences	73(1-2)	1-7	2024	○
13)	Sada H, Hinoi T, Niitsu H, Ohdan H, Yamamoto S, Endo S, Hida K, Kinugasa Y, Enomoto T, Maruyama S, Konishi F, Watanabe M, Sugihara K, Murata K, Horie H, Okajima M, Yamagishi S, Fujii S, Hazama S, Miyake Y, Kurose Y, Takii Y, Hayashi K, Munakata Y, Naito T, Saida Y, Shimamura T, Suda T, Miyajima N, Tanaka I, Goto M, Sakamoto K, Kinugasa Y, Saito S, Kubo Y, Okita K, Furuhashi T, Yatsuoka T, Tashiro J, Yamaguchi S, Ito M, Saito N, Hamada M, Kokuba Y, Kinjo Y, Sakai Y, Ueki T, Naito M, Kuroyanagi H, Ueno M, Akamoto S, Nishimura J, Hasegawa J, Kanazawa A, Maeda K, Hirakawa K, Yasui M, Tanaka K, Okuda J, Akagi T, Inomata M, Kitano S, Yamamoto D, Bando H, Shiozawa K, Kanehira E	Right-sided versus left-sided colorectal cancer in elderly patients: a sub-analysis of a large multicenter case-control study in Japan	Surgery Today	54(10)	1173-1183	2024	
14)	Chhoung C, Ko K, Ouoba S, Phyo Z, Akuffo G.A, Sugiyama A, Akita T, Sasaki H, Yamamoto T, Takahashi K, Tanaka I	Sustained applicability of SARS-CoV-2 variants identification by Sanger Sequencing Strategy on emerging various SARS-CoV-2 Omicron variants in Hiroshima, Japan	BMC Genomics	25(1)	1063	2024	
15)	Ko K, Lokteva L.M, Akuffo G.A, Phyo Z, Chhoung C, Bunthen E, Ouoba S, Sugiyama A, Akita T, Rattana K, Vichit O, Takahashi K, Tanaka I	A comparative study of extraction free detection of HBV DNA using sodium dodecyl sulfate, N-lauroylsarcosine sodium salt, and sodium dodecyl benzene sulfonate	Scientific Reports	14(1)	25442	2024	○
16)	El Ekiaby M, Tanaka I, van Drimmelen H, Allain JP, Lelie N	Infectivity of Hepatitis B Virus Surface Antigen-Positive Plasma With Undetectable HBV-DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?	Journal of Viral Hepatitis	31(11)	700-709	2024	○
17)	Satake M, Sugiyama M, Mizokami M, Tanaka I	Incidences of new hepatitis B infection and anti-hepatitis B core-negative occult hepatitis B infection among Japanese blood donors in relation to anti-hepatitis B surface antigen levels	Journal of Medical Virology	96(7)	e29823	2024	○
18)	Ouoba S, Sugiyama A, Ko K, Mirzaev U.K, Abe K, Bunthen E, Phyo Z, Khalilov K.K, Kurisu A, Akita T, Takahashi K, Sasaki H, Yamamoto T, Tanaka I	Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleocapsid assays for SARS-CoV-2	Journal of Medical Virology	96(8)	e29826	2024	
19)	Shimohara C, Kagaya A, Akita T, Tsukue R, Shimohara A, Machizawa M.G, Yamawaki S, Tanaka I, Okamura H	Changes in interoception before and after treatment in patients with alcohol use disorder	Neuropsychopharmacology Reports	44(4)	792-797	2024	
20)	Phyo Z, Ko K, Ouoba S, Sugiyama A, Mirzaev U.K, Akuffo G.A, Chhoung C, Akita T, Tanaka I	Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis	Plos One	19(9)	e0307872	2024	○

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
21)	Akuffo G.A, Ouoba S, Ko K, Chhoung C, Phyo Z, Mirzaev U.K, <u>Sugiyama A, Akita T, Tanaka J</u>	Assessing the diagnostic accuracy of serological tests for hepatitis delta virus diagnosis: a systematic review and meta-analysis	Scientific Reports	14(1)	18475	2024	○
22)	Kurose M, Yamamoto A, Elsayed A.M.A, Lawal-Ayinde B.M, Nomura T, Higashiura A, Irie T, Fukushi M, Kanda M, Tahara H, Morita D, Kuroda T, Ko K, Takahashi K, <u>Tanaka J</u> , Sakaguchi T	Viral coexistence and insertional mutations in the ORF8 region of SARS-CoV-2: A possible mechanism of nucleotide insertion	Virus Research	350()	199478	2024	
23)	Razavi-Shearer DM, Buti M, Tacke F, Terrault NA, Zeuzem S, Abbas Z, Aghemo A, Akarca US, Al Masri NM, Alalwan AM, Blomé MA, Aleman S, Alghamdi AS, Alghamdi M, Alghamdi S, Al-Hamoudi WK, Ali E, Aljumah AA, Altraif IH, Amarsanaa J, Asselah T, Baatarkhuu O, Babameto A, Ben-Ari Z, Berg T, Biondi MJ, Braga WSM, Brandao-Mello CE, Brown RS, Brunetto MR, Cabezas J, Cardoso M, Chan HLY, Cheinquer H, Chen CJ, Chen PJ, Chien CH, Child H, Chuang WL, Garza LEC, Coco B, Coffin CS, Coppola N, Cornberg M, Craxi A, Crespo J, Cuko L, De Ledinghen V, Duberg AS, Etzion O, Ferraz MLG, Ferreira PRA, Forns X, Foster GR, Fung J, Gaeta GB, García-Samaniego J, Genov J, Gheorghe LS, Gholam PM, Gish RG, Glenn J, Goldis A, Hamid SS, Hercun J, Hsu YC, Hu CC, Huang JF, Idilman R, Jafri WSM, Janjua N, Jelev D, Jerkeman A, Jia JD, Kåberg M, Kaita KDE, Kao JH, Khan AG, Kim DY, Kondili LA, Lagging M, Lampertico P, Lázaro P, Lazarus J, Lee MH, Lim YS, Lobato CMO, Macedo G, Marinho RT, Marotta PJ, Martins A, Mendes-Correa MC, Méndez-Sánchez N, Navas MC, Ning Q, Örmeci N, Orrego M, Osiowy C, Pan CQ, Pessoa MG, Piracha ZZ, Pop C, Ramos JAP, Qureshi H, Raimondo G, Ramji A, Razavi-Shearer K, Ribeiro S, Ríos-Hincapié CY, Rodríguez M, Rosenberg WMC, Roulot D, Ryder SD, Saeed U, Safadi R, Sanai FM, Sanchez-Avila JF, Santantonio TA, Sarrazin C, Seto WK, Shouval D, Simonova MY, <u>Tanaka J</u> , Tergast TL, Tsendsuren O, Valente C, Villalobos-Salcedo JM, Voeller AS, Waheed Y, Wong GLH, Wong VWS, Wu JC, Yang H, Yip TCF, Yu ML, Yuen MF, Yurdaydin C, Zuckerman E, Razavi HA	Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories	Journal of Hepatology	80(2)	232-242	2024	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
24)	Bastard P, Gervais A, Taniguchi M, Saare L, Särekanu K, Le Voyer T, Philippot Q, Rosain J, Bizien L, Asano T, Garcia-Prat M, Parra-Martínez A, Migaud M, Tsumura M, Conti F, Belot A, Riviére JG, Morio T, Tanaka J , Javouhey E, Haerynck F, Duvlis S, Ozcelik T, Keles S, Tandjaoui-Lambiotte Y, Escoda S, Husain M, Pan-Hammarström Q, Hammarström L, Ahlijah G, Haidar AA, Soudee C, Arseguet V, Abolhassani H, Sahanic S, Tancevski I, Nukui Y, Hayakawa S, Chrousos GP, Michos A, Tatsi EB, Filippatos F, Rodriguez-Palmero A, Troya J, Tipu I, Meyts I, Roussel L, Ostrowski SR, Schidlowski L, Prando C, Condino-Neto A, Cheikh N, Bousfiha AA, El Bakkouri J, Peterson P, Pujol A, Lévy R, Quartier P, Vinh DC, Boisson B, Béziat V, Zhang SY, Borghesi A, Pession A, Andreacos E, Marr N, Mentis AFA, Mogensen TH, Rodríguez-Gallego C, Soler-Palacin P, Colobran R, Tillmann V, Neven B, Trouillet-Assant S, Brodin P, Abel L, Jouanguy E, Zhang Q, Martínón-Torres F, Salas A, Gómez-Carballa A, Gonzalez-Granado LI, Kisand K, Okada S, Puel A, Cobat A, Casanova JL	Higher COVID-19 pneumonia risk associated with anti-IFN- α than with anti-IFN- ω auto-Abs in children	Journal of Experimental Medicine	221(2)	e20231353	2024	
25)	Toyoda H , Tada T, Uojima H, Nozaki A, Chuma M, Takaguchi K, Hiraoka A, Abe H, Itobayashi E, Matsuura K, Atsukawa M, Watanabe T, Shimada N, Nakamuta M, Kojima M, Tsuji K, Mikami S, Ishikawa T, Yasuda S, Tsutsui A, Arai T, Kumada T, Tanaka Y, Tanaka J , Chayama K	Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma	Journal of Gastroenterology and Hepatology	39(5)	949-954	2024	○
26)	Ishimaru T, Yamaguchi T, Saito T, Hattori Y, Ono T, Arai Y, Hasegawa Y, Shiga H, Tamaki K, Tanaka J , Tsuga K, Abekura H, Miyawaki S, Maeda-Lino A, Mikami S, Gotouda A, Satoh K, Shimizu K, Kato Y, Namita T	Actual state of the diurnal masseteric electromyogram: Differences between awareness and non-awareness of awake bruxism	Journal of Prosthodontic Research	68(3)	456-465	2024	
27)	Kumada T, Toyoda H , Ogawa S, Gotoh T, Yoshida Y, Yamahira M, Hirooka M, Koizumi Y, Hiasa Y, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Tanaka J , Shimizu M	Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study	Hepatology Research	54(9)	851-858	2024	○
28)	Kumada T, Toyoda H , Ogawa S, Gotoh T, Suzuki Y, Sugimoto K, Yoshida Y, Kuroda H, Kamada Y, Sumida Y, Ito T, Akita T , Tanaka J	Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease	Liver International	44(7)	1700-1714	2024	○
29)	Kumada T, Toyoda H , Ogawa S, Gotoh T, Suzuki Y, Imajo K, Sugimoto K, Kakegawa T, Kuroda H, Yasui Y, Tamaki N, Kurosaki M, Izumi N, Akita T , Tanaka J , Nakajima A	Advanced-fibrosis leads to overestimation of steatosis with quantitative ultrasound in individuals without hepatic steatosis	Ultrasonography	43(2)	121-131	2024	○
30)	Sakoi N, Mori Y, Tsugawa Y, Tanaka J , Fukuma S	Early-Stage Chronic Kidney Disease and Related Health Care Spending	JAMA Network Open	7(1)	e2351518	2024	
31)	Kariyama K, Kawanaka M, Nouse K, Wakuta A, Shiota S, Kurisu A, Sugiyama A , Akita T , Kumada T, Tanaka J	Identification of risk groups for advanced liver fibrosis in the general population using the Fibrosis-3 index	JGH Open	8(7)	e70010	2024	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
32)	Ogawa S, Kumada T, Gotoh T, Niwa F, <u>Toyoda H</u> , <u>Tanaka J</u> , Shimizu M	A comparative study of hepatic steatosis using two different qualitative ultrasound techniques measured based on magnetic resonance imaging-derived proton density fat fraction	Hepatology Research	54(7)	638-654	2024	○
33)	<u>Sugiyama A</u> , Takafuta T, Sato T, Kitahara Y, Yoshinaga Y, Abe K, Chanroth C, Ataa AG, Phyo Z, Kurisu A, Ko K, <u>Akita T</u> , Kishita E, Kuwabara M, <u>Tanaka J</u>	Natural course of post-COVID symptoms in adults and children	Scientific reports	14(1)	3884	2024	
34)	Mirzaev U.K, Ouoba S, Ko K, Phyo Z, Chhoung C, Ataa A.G, <u>Sugiyama A</u> , <u>Akita T</u> , <u>Tanaka J</u>	Systematic review and meta-analysis of hepatitis E seroprevalence in Southeast Asia: a comprehensive assessment of epidemiological patterns	BMC Infectious Diseases	24(1)	525	2024	○
35)	Sok S, Chhoung C, Sun B, Ko K, <u>Sugiyama A</u> , <u>Akita T</u> , Fukuma S, <u>Tanaka J</u>	Knowledge of hepatitis B infection, hepatitis B vaccine, and vaccination status with its associated factors among healthcare workers in Kampot and Kep Provinces, Cambodia	BMC Infectious Diseases	24(1)	658	2024	○
36)	Abe K, <u>Sugiyama A</u> , Ito N, Miwata K, Kitahara Y, Okimoto M, Mirzaev U, Kurisu A, <u>Akita T</u> , Ko K, Takahashi K, Kubo T, Takafuta T, <u>Tanaka J</u>	Variant-specific symptoms after COVID-19: a hospital-based study in Hiroshima	Journal of epidemiology	34(5)	238-246	2024	
37)	Mirzaev U.K, Ko K, Bunthen E, Phyo Z, Chhoung C, Ataa A.G, <u>Sugiyama A</u> , <u>Akita T</u> , Takahashi K, <u>Tanaka J</u>	Epidemiological assessment of hepatitis E virus infection among 1565 pregnant women in Siem Reap, Cambodia using an in-house double antigen sandwich ELISA	Hepatology Research	54(10)	899-911	2024	○
38)	Okada K, Nakayama Y, Xu J, Cheng Y, <u>Tanaka J</u>	A nation-wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	Hepatology Research	54(11)	1004-1015	2024	○
39)	Kimura M, Nishikawa T, <u>Shimakami T</u> , Terashima T, Horii R, Fukuda M, Yoshita M, Takata N, Hayashi T, Funaki M, Nio K, Takatori H, Arai K, Yamashita T, Honda M, <u>Tanaka J</u> , Kaneko S, Yamashita T	Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis	Global Health & Medicine	6(6)	404-415	2024	○
40)	Yamaguchi D, Chimed-Ochir O, Yumiya Y, Kishita E, <u>Akita T</u> , <u>Tanaka J</u> , Kubo, T	Potential Risk Factors to COVID-19 Severity: Comparison of SARS-CoV-2 Delta- and Omicron-Dominant Periods	International Journal of Environmental Research and Public Health	21(3)	322	2024	
41)	<u>Toyoda H</u> , Koshiyama Y, Yasuda S, Kumada T, Chayama K, <u>Akita T</u> , <u>Tanaka J</u>	Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection	Journal of Viral Hepatitis	31(3)	137-142	2024	○
42)	Kurisu A, <u>Sugiyama A</u> , <u>Akita T</u> , Takumi I, Yamamoto H, Iida K, <u>Tanaka J</u>	Incidence and prevalence of epilepsy in Japan: a retrospective analysis of insurance claims data of 9,864,278 insured persons	Journal of epidemiology	34(2)	70-75	2024	
43)	Yamagishi N, Ando N, Yoshimasa T, Toda S, Sobata R, Goto N, Matsubayashi K, Satake M, <u>Tani Y</u>	The first case of transfusion-transmitted hepatitis B virus genotype I in Japan.	Transfusion	Online ahead of print		2025	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
44)	Tai-Chung Tseng, <u>Tetsuya Hosaka</u> , Mei-Hung Pan, Chun-Jen Liu, Fumitaka Suzuki, Chien-Jen Chen, Tung-Hung Su, Hiromitsu Kumada, Wan-Ting Yang, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen, Hwai-I Yang, Jia-Horng Kao	Higher Level of Hepatitis B Surface Antigen Associated with Delayed Development of Hepatocellular Carcinoma in Immune-tolerant Patients.	Hepatology	in press		2025	○
45)	Tanaka T, <u>Koga H</u> , Suzuki H, Iwamoto H, Sakaue T, Masuda A, Nakamura T, Akiba J, Yano H, Torimura T, Kawaguchi T.	Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.	Hepatol Int	18(3)	984-997	2024	
46)	Suzuki H, Iwamoto H, Tanaka T, Sakaue T, Imamura Y, Masuda A, Nakamura T, <u>Koga H</u> , Hoshida Y, Kawaguchi T.	Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.	Hepatol Int	18(2)	610-622	2024	
47)	Masuda A, Nakamura T, Iwamoto H, Suzuki H, Sakaue T, Tanaka T, Imamura Y, Mori N, <u>Koga H</u> , Kawaguchi T.	Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice.	Cytotherapy	26(8)	899-909	2024	
48)	Nakamura T, Masuda A, Kako M, Enomoto H, Kaibori M, Fujita Y, Tanizawa K, Ioji T, Fujimori Y, Fukami K, Hazama T, Iwamoto H, Kako Y, Kobayashi K, <u>Koga H</u> , Nagafuji K, Ohtake T, Suzuki H, Takashima T, Tsukiyama T, Uojima H, Yamahara K, Yamakado K, Yamamoto H, Yoh K, Yoshihara S, Kawamoto A, Nishiguchi S, Kobayashi S, Torimura T, Kawaguchi T.	Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial.	Regen Ther	27	455-463	2024	
49)	Suzuki H, Sakai M, Iwamoto H, Shimose S, Niizeki T, Nakano M, Shirono T, Noda Y, Moriyama E, Kuromatsu R, <u>Koga H</u> , Kawaguchi T.	The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma.	Gastro Hep Adv	3(4)	506-509	2024	
50)	Masubuchi H, Imamura Y, Kawaguchi T, <u>Koga H</u> .	Leucine drives LAT1-related SNAIL upregulation in glucose-starved pancreatic cancer cells.	Med Mol Morphol	58(1)	23-33	2024	
51)	Sakai M, Iwamoto H, Shimose S, Niizeki T, Nakano M, Shirono T, Noda Y, Moriyama E, Suzuki H, <u>Koga H</u> , Kuromatsu R, Kawaguchi T.	Dose-Reduction of Bevacizumab in Atezolizumab plus Bevacizumab Therapy Extends Treatment duration with Disease Control in Patients with Hepatocellular Carcinoma.	Oncology	12	1-12	2024	
52)	Sakaue T, <u>Koga H</u> , Iwamoto H, Nakamura T, Masuda A, Tanaka T, Suzuki H, Suga H, Hirai S, Hisaka T, Naito Y, Ohta K, Nakamura KI, Selvendiran K, Okabe Y, Torimura T, Kawaguchi T.	Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma.	Gastro Hep Adv	3(6)	761-772	2024	
53)	Sakaue T, Dorayappan KDP, Zingarelli R, Khadraoui W, Anbalagan M, Wallbillich J, Bognar B, Wanner R, Cosgrove C, Suarez A, <u>Koga H</u> , Maxwell GL, O'Malley DM, Cohn DE, Selvendiran K.	Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.	Oncogene	43(49)	3586-3597	2024	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
54)	Moriyama E, Shimose S, Niizeki T, Iwamoto H, Tanaka M, Shirono T, Noda Y, Nakano M, Kuromatsu R, <u>Koga H</u> , Kawaguchi T.	Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.	Curr Oncol	31(10)	5821-5831	2024	
55)	Suzuki H, Fukuda M, Shirono T, Kondo R, Tanaka T, Niizeki T, Akiba J, <u>Koga H</u> , Kawaguchi T.	A Rare Case of Primary Hepatic Undifferentiated Pleomorphic Sarcoma: Exploring Cancer-related Gene Mutations.	Intern Med	doi: 10.2169/intermedicine.4368-24.		2024	
56)	Inukai Y, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Shimizu T, Hattori M, Takeyama T, Ando Y, Nishikawa T, Morita K, <u>Toyoda H</u> , Ishigami M, Kawashima H	Impact of cardiometabolic factors on fibrosis progression in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease.	J Dig Dis			in press	
57)	Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.	Hepatol Res			in press	
58)	Kimura M, Yamada S, Go M, Yasuda S, <u>Toyoda H</u> , Usami E	Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma.	J Oncol Pharm Pract			in press	
59)	Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M	Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study.	Oncology			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
60)	Sometani E, Hikita H, Murai K, <u>Toyoda H</u> , Tanaka S, Oze T, Sung J, Shimoda A, Fukuoka M, Shigeno S, Fukutomi K, Shirai K, Tahata Y, Saito Y, Nishio A, Furuta K, Kodama T, Sakamori R, Tatsumi T, Mita E, Umezawa A, Tanaka Y, Takehara T	High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues.	Hepatol Res			in press	
61)	<u>Toyoda H</u> , Hiraoka A, Ochi H, Tsuji K, Tajiri K, Tani J, Tada T, Okubo T, Atsukawa M, Hirooka M, Itobayashi E, Hatanaka T, Kariyama K, Ishikawa T, Kuroda H, Takaguchi K, Kosaka H, Kawada K, Kakizaki S, Yada Y, Ogawa C, Nishimura T, Yasuda S, Deguchi A, Itokawa N, Arai T, Tsutsui A, Naganuma A, Enomoto H, Kaibori M, Nouse K, Hiasa Y, Kumada T, <u>Akita T</u> , <u>Tanaka J</u> , Johnson PJ	Prognostic significance of the BALAD serological model in systemic therapies for hepatocellular carcinoma: a personalized approach to the prediction of survival benefit.	JCO Clin Cancer Inform			in press	
62)	Kariyama K, Nouse K, Hiraoka A, <u>Toyoda H</u> , Tada T, Tsuji K, Ishikawa T, Hatanaka T, Itobayashi E, Takaguchi K, Tsutsui A, Naganuma A, Yasuda S, Kakizaki S, Wakuta A, Shiota S, Kumada T	Identification of high-risk group for diabetes mellitus-associated hepatocellular carcinoma using non-invasive test for liver fibrosis.	Eur J Gastroenterol Hepatol			in press	
63)	Naganuma A, Kakizaki S, Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, <u>Toyoda H</u> , Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Yata Y, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Impact of time-of-day atezolizumab-bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: a retrospective multicenter study.	Hepatol Res			in press	
64)	Yasuda T, Ito T, Ishikawa T, Mizuno K, Yamamoto T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Koshiyama Y, Yasuda S, <u>Toyoda H</u> , Ando Y, Shimoyama Y, Kawashima H	Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors.	Dig Liver Dis			in press	
65)	Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, Ohama H, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, <u>Toyoda H</u> , Matono T, Yata Y, Ogawa C, Naganuma A, Tani J, Atsukawa M, Nishimura T, Tajiri K, Kawata K, Kosaka H, Kuroda H, Hirooka M, Nishikawa H, Tada F, Nakamura S, Kanayama Y, Nouse K, Tanaka H, Tanaka K, Imai M, Tsutsui A, Nagano T, Aoki T, Koshiyama Y, Morishita A, Itokawa N, Okubo T, Arai T, Fukunishi S, Noritake H, Nakamura Y, Yoshida O, Enomoto H, Kaibori M, Hiasa Y, Kumada T	Tumor markers as biomarkers for evaluating and monitoring therapeutic efficacy in the era of immunotherapy: is alpha-fetoprotein alone sufficient?	Oncology			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
66)	Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, <u>Toyoda H</u> , Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Tomomi Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M	Survival outcomes associated with radiological progressive disease subtypes in patients with atezolizumab and bevacizumab-treated HCC.	J Gastroenterol Hepatol			in press	
67)	Kim M, Yoon EL, Park H, Ito T, Ishigami M, Jo AJ, Lee CM, Kang BK, Kim HL, Arai T, Atsukawa M, Kawanaka M, <u>Toyoda H</u> , Yu ML, Jun DW, Nguyen MH	Limited use of FIB-4 in with type 2 diabetes patients under 65 years of age.	Hepatol Res			in press	
68)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, <u>Toyoda H</u> , Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T	Reliable performance of mALBI grade-based risk models for predicting the prognosis of patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab as first-line treatment: comparative analysis of 13 risk models.	J Gastroenterol Hepatol			in press	
69)	Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, <u>Toyoda H</u> , Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Evaluation of treatment outcomes using dNLR and GNRI in combination therapy with atezolizumab and bevacizumab for hepatocellular carcinoma.	Cancer Med	14	e70618	2025	
70)	<u>Toyoda H</u>	Letter: Identifying the best model for predicting post-SVR HCC.	Aliment Pharmacol Ther	61	748-749	2025	○
71)	Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Tanaka H, Nishikawa H, Shibata H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T	Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.	Sci Rep	15	72	2025	
72)	Shibata N, Ito T, Morita Y, <u>Toyoda H</u> , Kanzaki Y, Watanabe N, Yoshioka N, Miyazawa H, Shimojo K, Ohi T, Goto H, Karasawa H, Morishima I	Impact of the fibrosis-4 index in patients with ST-elevated myocardial infarction.	Coron Artery Dis	36	99-107	2025	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
73)	Siriwong N, Sriphoosanaphan S, Decharatanachart P, Yongpisarn T, Apiparakoon T, Tiyyarattanachai T, Kerr S, Treeprasertsuk S, Hagstrom H, Akbari C, Ekstedt M, Ito T, Ishigami M, <u>Toyoda H</u> , Hino K, Kawanaka M, Sumida Y, Seko Y, Peleg N, Shlomai A, Yip TCF, Wong GLH, Chaiteerakij R	Role of non-invasive tests on the prediction of hepatocellular carcinoma in non-alcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data.	Eur J Gastroenterol Hepatol	37	358-369	2025	
74)	Hatanaka T, Saito N, Kakizaki S, Hiraoka A, Tada T, Kariyama K, Tani J, Takaguchi K, Itobayashi E, Ishikawa T, <u>Toyoda H</u> , Kawata K, Naganuma A, Yata Y, Ohama H, Matono T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Nakamura S, Kumada T	Factors affecting an increase in spleen volume and association of spleen volume variation with the clinical outcomes of atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a retrospective analysis.	Oncology	103	94-106	2025	
75)	Kim J, Ito T, Arai T, Atsukawa M, Kawanaka M, <u>Toyoda H</u> , Honda T, Yu ML, Yoon EL, Jun DW, Cha K, Nguyen MH	Modified FIB-4 index in type 2 diabetes mellitus with steatosis: a non-linear predictive model for advanced hepatic fibrosis.	Diagnostics	14	2500	2024	
76)	Hirano Y, Nouse K, Kariyama K, Hiraoka A, Shiota S, Wakuta A, Yasuda S, <u>Toyoda H</u> , Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Tada T, Itobayashi E, Ishikawa T, Shimada N, Takaguchi K, Tsutsui A, Nagano T, Imai M, Nakamura S, Kumada T	Prognostic efficacy of the albumin grade in patients with hepatocellular carcinoma	Acta Med Okayama	78	377-386	2024	
77)	Tada T, Kurosaki M, <u>Toyoda H</u> , Tamaki N, Yasui Y, Nakamura S, Mori N, Tsuji K, Ochi H, Akahane T, Kobashi H, Fujii H, Marusawa H, Kondo M, Urawa N, Yoshida H, Uchida Y, Morita A, Hasebe C, Mitsuda A, Ogawa C, Narita R, Kubotsu Y, Matsushita T, Shigeno M, Okamoto E, Okada K, Kasai T, Ishii T, Nonogi M, Yasuda S, Koshiyama Y, Kumada T, Izumi N	Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.	Liver Int	44	3060-3071	2024	○
78)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, <u>Toyoda H</u> , Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: comparative analysis of conversion, partial response and complete response patients.	Aliment Pharmacol Ther	60	1361-1373	2024	
79)	Ishiba H, Fujii H, Kamada Y, Sumida Y, Takahashi H, Seko Y, <u>Toyoda H</u> , Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Fukushima H, Miyoshi E, Aishima S, Itoh Y, Okanoue T, Nakajima A.	Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.	Hepatol Commun	9	e0563	2024	
80)	Umezu T, Mori T, <u>Toyoda H</u> , Kanekura K, Tamori A, Ochiya T, Kuroda M, Akutsu T, Murakami Y	Analysis of carcinogenic involvement of miRNA pattern in peripheral non-cancerous tissues and chronic viral liver injury.	Int J Mol Sci	25	7858	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
81)	Shibata N, Morita Y, Ito T, Kanzaki Y, Watanabe N, Yoshioka N, Arao Y, Yasuda S, Koshiyama Y, <u>Toyoda H</u> , Morishima I	A machine learning algorithm for stratification of risk of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease.	Eur J Intern Med	129	62-70	2024	
82)	Ji F, Tran S, Ogawa E, Huang CF, Suzuki T, Wong YJ, <u>Toyoda H</u> , Jun DW, Li L, Uojima H, Nozaki A, Chuma M, Tseng CH, Hsu YC, Ishigami M, Honda T, Atsukawa M, Haga H, Enomoto M, Trinh H, Preda CM, Vutien P, Landis C, Lee DH, Watanabe T, Takahashi H, Abe H, Asai A, Eguchi Y, Li J, Wang X, Li J, Liu J, Liang J, Lam CPM, Huang R, Ye Q, Pan H, Zhang J, Cai D, Wang Q, Huang DQ, Wong G, Wong VWS, Li J, Do S, Furusyo N, Nakamuta M, Nomura H, Kajiwaru E, Yoon EL, Ahn SB, Azuma K, Dohmen K, An J, Song DS, Cho HC, Kawano A, Koyanagi T, Ocho A, Satoh T, Takahashi K, Yeh ML, Tsai PC, Yasuda S, Zhao Y, Liu Y, Okubo T, Itokawa N, Jun MJ, Ishikawa T, Takaguchi K, Senoh T, Zhang M, Zhao C, Alecu RI, Tay WX, Devan P, Liu JK, Kozuka R, Vargas-Accarino E, Do AT, Maeda M, Chuang WL, Huang JF, Dai CY, Cheung R, Buti M, Niu J, Xie W, Ren H, Lim SG, Wu C, Yuen MF, Shang J, Zhu Q, Ueno Y, Tanaka Y, Hayashi J, Yu ML, Nguyen MH	Real-world effectiveness and tolerability of interferon-free direct-acting antiviral for 15,849 patients with chronic hepatitis C: a multinational cohort study.	J Clin Transl Hepatol	12	646-658	2024	
83)	Miyamoto H, Kondo Y, Itobayashi E, Uehara M, Hiraoka A, Kudo M, Kakizaki S, Kagawa T, Miura S, Suzuki T, Sugi K, Suyama K, Beppu T, <u>Toyoda H</u> , Yoshiji H, Uojima H, Miyase S, Inoue K, Tamori A, Ito T, Shimose S, Suda G, Hayashi T, Onishi M, Narahara S, Watanabe T, Iwatsuki M, Fukushima S, Tanaka Y	Evaluation of the associations of IL7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: a replication study of a Japanese population, based on the findings of a Caucasian genome-wide association study.	Hepatol Res	54	1215-1225	2024	
84)	Kimura M, Yamada S, Go M, Yasuda S, <u>Toyoda H</u> , Usami E	Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: a comparison of lenvatinib as 1st or 2nd line treatment.	Oncol Lett	28	330	2024	
85)	Kumazaki S, Hikita H, Tahata Y, Sung JH, Fukumoto K, Myojin Y, Sakane S, Murai K, Sasaki Y, Shirai K, Saito Y, Kodama T, Kakita N, Takahashi H, <u>Toyoda H</u> , Suda G, Morii E, Kojima T, Ebihara T, Shimizu K, Sasaki Y, Tatsumi T, Takehara T	Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis.	Aliment Pharmacol Ther	60	327-339	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
86)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A	Adverse events as potential predictive factors of activity in patients with advanced HCC treated with atezolizumab plus bevacizumab.	Target Oncol	19	645-659	2024	
87)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, <u>Toyoda H</u> , Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouse N, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M	Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.	Aliment Pharmacol Ther	60	233-245	2024	
88)	<u>Atsukawa M</u> , Tsubota A, Kondo C, <u>Toyoda H</u> , Takaguchi K, Nakamuta M, Watanabe T, Morishita A, Tani J, Okubo H, Hiraoka A, Nozaki A, Chuma M, Kawata K, Uojima H, Ogawa C, Asano T, Mikami S, Kato K, Matsuura K, <u>Ikegami T</u> , Ishikawa T, Tsuji K, Tada T, Tsutsui A, Senoh T, Kitamura M, Okubo T, Arai T, Fukunishi S, Kohjima M, Akahane T, Nishikawa H, Iwasa M, Tanaka Y, Iwakiri K	ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.	J Gastroenterol	59	709-718	2024	○
89)	Sumida Y, <u>Toyoda H</u> , Yasuda S, Kimoto S, Sakamoto K, Nakade Y, Ito K, Osonoi T, Yoneda M	Comparison of efficacy between pemafibrate and omega-3-acid ethyl ester in the liver: the PORTRAIT study.	J Atheroscler Thromb	31	1620-1633	2024	
90)	Itokawa N, Atsukawa M, Tsubota A, Ishikawa T, <u>Toyoda H</u> , Takaguchi K, Watanabe T, Ogawa C, Hiraoka A, Okubo H, Uojima H, Chuma M, Nozaki A, Kato K, Mikami S, Tani J, Morishita A, Tada T, Asano T, Senoh T, Oikawa T, Okubo T, Kumada T, Iwakiri K	Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.	Hepatol Res	54	993-1003	2024	
91)	Sasaki K, Kawamura Y, Ogawa C, Yabushita K, Watanabe S, Hayashi H, Kochi T, Tomonari T, Ninomiya M, Takai K, Imajo K, Ito T, Kita R, Mawatari S, Nishina S, <u>Toyoda H</u>	Skill proficiency, efficacy, and safety of the transradial approach in transarterial treatments for hepatocellular carcinoma.	Cureus	16	e57800	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
92)	Chuma M, Uojima H, <u>Toyoda H</u> , Hiraoka A, Arase Y, Atsukawa M, Itokawa N, Okubo T, Tada T, Numata K, Morimoto M, Sugimori M, Nozaki A, Iwasaki S, Yasuda S, Koshiyama Y, Mishima Y, Tsuruya K, Tokoro C, Miura Y, Hidaka H, Kumada T, Kusano C, Kagawa T, Maeda S	Clinical significance of circulating biomarkers of immune checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.	Hepatol Int	18	1472-1485	2024	
93)	Tsutsumi T, Kawaguchi T, Fujii H, Kamada Y, Takahashi H, Kawanaka M, Sumida Y, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Nakajima A, Okanoue T.	Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: a multicenter study in Japan.	Aliment Pharmacol Ther	59	1559-1570	2024	
94)	Shibata N, Ito T, <u>Toyoda H</u> , Tanaka A, Morita Y, Kanzaki Y, Watanabe N, Yoshioka N, Yasuda S, Morishima I.	Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease.	Nutr Metab Cardiovasc Dis	34	2115-2123	2024	
95)	Sakata T, Yoshio S, Yamazoe T, Mori T, Kakazu E, Aoki Y, Aoyanagi N, Okamoto T, Ito T, <u>Toyoda H</u> , Kawaguchi T, Ono Y, Takahashi Y, Taketomi A, Kanto T	Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma.	Front Immunol	15	1389411	2024	
96)	Ohama H, Hiraoka A, Tada T, Kariyama K, Itobayashi E, Tsuji K, Ishikawa T, <u>Toyoda H</u> , Hatanaka T, Kakizaki S, Naganuma A, Tada F, Tanaka H, Nakamura S, Nouse K, Tanaka K, Kumada T	Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.	J Gastroenterol Hepatol	39	1394-1402	2024	
97)	Uojima H, Yamasaki K, Sugiyama M, Kage M, Ishii N, Shirabe K, Hidaka H, Kusano C, Murakawa M, Asahina Y, Nishimura T, Iijima H, Sakamoto K, Ito K, Amano K, Kawaguchi T, Tamaki N, Kurosaki M, Suzuki T, Matsuura K, Taketomi A, Joshita S, Umemura T, Nishina S, Hino K, <u>Toyoda H</u> , Yatsuhashi H, Mizokam M.	Quantitative measurements of M2BPGI depend on liver fibrosis and inflammation.	J Gastroenterol	59	598-608	2024	
98)	Kariyama K, Nouse K, Kawanaka M, Fujii H, <u>Toyoda H</u> , Iwaki M, Hayashi H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Kumada T, Okanoue T.	Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease.	Hepatol Res	54	912-920	2024	
99)	Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Hatanaka T, Tani J, Takaguchi K, Atsukawa M, Itobayashi E, Nishimura T, Tsuji K, Tajiri K, Ishikawa T, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ogawa C, Kakizaki S, Shimada N, Naganuma A, Kawata K, Kosaka H, Kuroda H, Matono T, Yata Y, Ochi H, Tada F, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T	Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.	Cancer Rep	7	e2042	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
100)	Kimura M, Yamada S, Go M, Yasuda S, <u>Toyoda H</u> , Usami E.	Evaluation of atezolizumab plus bevacizumab versus modified lenvatinib therapy in Child-Pugh A unresectable hepatocellular carcinoma.	Cancer Diagn Progn	4	122-128	2024	
101)	Hirooka M, Ogawa S, Koizumi Y, Yoshida Y, Goto T, Yasuda S, Yamahira M, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Hiasa Y, <u>Toyoda H</u> , Kumada T.	iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.	J Gastroenterol	59	504-514	2024	
102)	Sakane S, Hikita H, Shirai K, Sakamoto T, Narumi R, Adachi J, Kakita N, Yamada Y, <u>Toyoda H</u> , Takahashi H, Suda G, Kai M, Tahata Y, Sakamori R, Kumazaki S, Fukumoto K, Myojin Y, Murai K, Kodama T, Tatsumi T, Tomonaga T, Sakamoto N, Morii E, Takehara T.	Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.	Hepatol Commun	8	e0448	2024	
103)	Jang TY, Liang PC, Jun DW, Jung JH, <u>Toyoda H</u> , Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon EL, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino E, Abe H, Takahashi H, Inoue K, Yeh ML, Dai CY, Huang JF, Huang CF, Chuang WL, Nguyen MH, Yu ML.	Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: a multinational study.	J Gastroenterol Hepatol	39	1190-1197	2024	
104)	Kudaravalli S, Huang DQ, Yeh ML, Trinh L, Tsai PC, Hsu YC, Kam LY, Nguyen VH, Ogawa E, Lee DH, Ito T, Watanabe T, Enomoto M, Preda CM, Ko MKL, Hui RWH, Atsukawa M, Suzuki T, Marciano S, Barreira A, Do S, Uojima H, Takahashi H, Quek SXZ, Khine HHTW, Ishigami M, Itokawa N, Go MS, Kozuka R, Marin RI, Sandra I, Li J, Zhang JQ, Wong C, Yoshimaru Y, Vo DKH, Tseng CH, Lee CJ, Inoue K, Maeda M, Hoang JK, Chau A, Chuang WL, Dai CY, Huang JF, Huang CF, Buti M, Tanaka Y, Gadano AC, Yuen MF, Cheung R, Lim SG, Trinh HN, <u>Toyoda H</u> , Yu ML, Nguyen MH	Sex and ethnic disparities in hepatitis B evaluation and treatment: a real-world study from both East and West.	J Hepatol	81	33-41	2024	
105)	Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavarone M, Marra F, Foschi F, Tamburini E, Rossari F, Vitiello F, Bartalini L, Solda C, Tovoli F, Vivaldi C, Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V, Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Camera S, Foti S, Aldrighetti L, Cascinu S, Casadei-Gardini A, Piscaglia F	Impact of body mass index on the prognosis of unresectable HCC patients receiving first line lenvatinib or atezolizumab plus bevacizumab.	Liver Int	44	1108-1125	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
106)	Tada T, Kumada T, Hiraoka A, Kariyama K, Yasuda S, Tada F, Ohama H, Nouse K, Matono T, Nakamura S, <u>Toyoda H</u>	mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.	J Gastroenterol Hepatol	39	1164-1171	2024	
107)	Iwaki M, Fujii H, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study.	Clin Mol Hepatol	30	225-234	2024	
108)	Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini	Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study.	Liver Cancer	13	522-536	2024	
109)	Kariyama K, Nouse K, Hiraoka A, <u>Toyoda H</u> , Tada T, Tsuji K, Ishikawa T, Hatanaka T, Itobayashi E, Takaguchi K, Tsutsui A, Naganuma A, Yasuda S, Kakizaki S, Wakuta A, Shiota S, Kudo M, Kumada T	Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs ablation: a multicenter retrospective study.	J Liver Cancer	24	71-80	2024	
110)	Johnson PJ, Kalyuzhnyy A, Boswell E, <u>Toyoda H</u>	Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and management.	BJC Rep	2	39	2024	
111)	Johnson PJ, Bhatti E, <u>Toyoda H</u> , He S	Serological detection of HCC in full-application of machine learning and implications for the diagnostic models.	JCO Clin Cancer Inform	8	e2300119	2024	○
112)	Park JE, Nguyen VH, Tsai PC, <u>Toyoda H</u> , Leong J, Dr. Guy JE, Yeh ML, Huang CF, Yasuda S, Abe H, Hsu YC, Tseng CH, Liu J, Chen YL, Lin PY, Jun DW, Yoshimaru Y, Ogawa E, Ishigami M, Enomoto M, Tamori A, Uojima H, Wang XZ, Xu Q, Takahashi H, Eguchi Y, Inoue K, Huang DQ, Zhao WJ, Chuang WL, Dai CY, Huang JF, Barnett S, Maeda M, Cheung R, Landis C, Tanaka Y, Roberts LR, Schwartz ME, Kumada T, Yu ML, Nguyen MH.	Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.	Aliment Pharmacol Ther	59	742-751	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
113)	Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A	Safety and efficacy of lenvatinib in very elderly patients with unresectable hepatocellular carcinoma.	Target Oncol	19	29-39	2024	
114)	Arai T, Takahashi H, Seko Y, <u>Toyoda H</u> , Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, <u>Ikegami T</u> , Notsumata K, Oeda S, Atsukawa M, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Itoh Y, Nakajima A, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).	Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications.	Clin Gastroenterol Hepatol	22	789-797	2024	
115)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Aoki T, Tanaka K, Tanaka T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T.	Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: a multicenter study.	Hepatol Res	54	382-391	2024	
116)	Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Burgio V, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M	Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population.	Int J Cancer	154	1043-1056	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
117)	Huang DQ, Hoang JK, Kamal R, Tsai PC, <u>Toyoda H</u> , Yeh ML, Yasuda S, Leong J, Maeda M, Huang CF, Jun DW, Ishigami M, Tanaka Y, Uojima H, Ogawa E, Abe H, Hsu YC, Tseng CH, Alsudaney M, Yang JD, Yoshimaru Y, Suzuki T, Liu JK, Landis C, Dai CY, Huang JF, Chuang WL, Schwartz M, Dan YY, Esquivel C, Bonham A, Yu ML, Nguyen MH.	Antiviral therapy utilization and 10-year outcomes in resected HBV- and HCV-related hepatocellular carcinoma.	J Clin Oncol	42	790-799	2024	○
118)	Ogawa E, Jun DW, <u>Toyoda H</u> , Hsu YC, Yoon EL, Ahn SB, Yeh ML, Do S, Trinh HM, Takahashi H, Enomoto M, Kawada N, Yasuda S, Tseng CH, Kawashima K, Lee HA, Inoue K, Haga H, Do AT, Maeda M, Hoang JH, Cheung R, Ueno Y, Eguchi Y, Furusyo N, Yu ML, Tanaka Y, Nguyen MH	Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: a prospective, multinational study.	Aliment Pharmacol Ther	59	239-248	2024	
119)	Jang TY, Liang PC, Jun DW, Jung JH, <u>Toyoda H</u> , Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon E, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino E, Abe H, Takahashi H, Inoue K, Yeh ML, Dai CY, Huang JF, Huang CF, Chuang WL, Nguyen MH, Yu ML	Pre-treatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.	Kaohsiung J Med Sci	40	188-197	2024	
120)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M	Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.	Liver Int	44	113-124	2024	
121)	<u>Toyoda H</u> , Kikuchi K	Author response to management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.	Ther Apher Dial	28	160-161	2024	○
122)	Endo K, Kakisaka K, Abe T, Yusa K, Nakaya I, Watanabe T, Suzuki A, Yoshida Y, Oikawa T, <u>Miyasaka A</u> , Kuroda H, Matsumoto T	Positive impact of obesity on the prognosis of liver cirrhosis	J Gastroenterol Hepatol.	39	1663-1672	2024	
123)	Endo K, Kakisaka K, Abe T, Yusa K, Nakaya I, Watanabe T, Abe H, Suzuki A, Yoshida Y, Oikawa T, <u>Miyasaka A</u> , Kuroda H, Matsumoto T	Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	Hepatol Res.	54	1158-1173	2024	
124)	Sasaki T, Kakisaka K, <u>Miyasaka A</u> , Nishiya M, Yanagawa N, Kuroda H, Matsumoto T, Takahashi M, Okamoto H	Spontaneous reactivation of hepatitis B virus with multiple novel mutations in an elderly patient with resolved hepatitis B virus infection	Clin J Gastroenterol	17	638-690	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
125)	Nio K, <u>Shimakami T</u> , Terashima T, Yanagi M, Toyama T, Koshikawa N, Nakagawa M, Yoshida E, Yoshimura T, Seiki M, Honda M, Yamashita T.	Serum laminin γ 2 monomer as a predictive biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a retrospective cohort study.	Scientific Reports	14(1)	25395	2024	
126)	Murayama A, Igarashi H, Yamada N, Aly HH, Toyama M, Isogawa M, <u>Shimakami T</u> , Kato T.	Exploring the tolerable region for HiBiT tag insertion in the hepatitis B virus genome.	mSphere	9(10)	e0051824	2024	
127)	Yoshita M, Funaki M, <u>Shimakami T</u> , Kakuya M, Murai K, Sugimoto S, Kawase S, Matsumori K, Kawane T, Nishikawa T, Nakamura A, Suzuki R, Ishida A, Kawasaki N, Sato Y, Li YY, Sumiyadorj A, Nio K, Takatori H, Kawaguchi K, Kuroki K, Kato T, Honda M, Yamashita T.	High-Throughput Screening of Antiviral Compounds Using a Recombinant Hepatitis B Virus and Identification of a Possible Infection Inhibitor, Skimmianine.	Viruses	16(8)	1346	2024	
128)	Okada H, Sakamoto T, Nio K, Li Y, Kuroki K, Sugimoto S, <u>Shimakami T</u> , Doi N, Honda M, Seiki M, Kaneko S, Yamashita T.	Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice.	Molecular Therapy - Methods & Clinical Development.	32(3)	101289	2024	
129)	Miura M, Nishino M, Kawaguchi K, Li S, <u>Shimakami T</u> , Tamai T, Nakagawa H, Terashima T, Iida N, Takatori H, Arai K, Sakai Y, Yamashita T, Honda M, Kaneko S, Mizukoshi E, Yamashita T.	Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy.	PLoS One	19(5)	e0299424	2024	
130)	Lyu J, Okada H, Sunagozaka H, Kawaguchi K, <u>Shimakami T</u> , Nio K, Murai K, Shirasaki T, Yoshida M, Arai K, Yamashita T, Tanaka T, Harada K, Takamura T, Kaneko S, Yamashita T, Honda M.	Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis.	Hepatology Communications	8(5)	e0425	2024	
131)	Shimizu R, Murai K, Tanaka K, Sato Y, Takeda N, Nakasyo S, Shirasaki T, Kawaguchi K, <u>Shimakami T</u> , Nio K, Nakaya Y, Kagiwada H, Horimoto K, Mizokami M, Kaneko S, Murata K, Yamashita T, Honda M.	Nucleos(t)ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes	Hepatology Communications	8(1)	e0351	2024	
132)	Murakami M, Fujii N, Kanda E, <u>Kikuchi K</u> , et al	Association between Timing of Vascular Access Creation and Mortality in Patients Initiating Hemodialysis: A Nationwide Cohort Study in Japan	Am J Nephrol	55(6)	647-656	2024	
133)	Yoshifuji A, Toda M, Oyama E, Nakayama T, Mise-Omata S, <u>Kikuchi K</u> , et al	Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients	Clin Exp Nephro	28(7)	674-682	2024	
134)	Sugawara Y, Iwagami M, <u>Kikuchi K</u> , et al	Coronavirus disease 2019 vaccination effectiveness based on the 2021 Japanese dialysis registry.	Nephrology (Carlton)	29(10)	671-679	2024	
135)	Abe M, <u>Kikuchi K</u> , et al	Intermittent infusion hemodiafiltration is associated with improved survival compared to hemodialysis	Renal Replacement Therapy	10	https://rrtjournal.biomedcentral.com/articles/10.1186/s41100-024-00540-4	2024	
136)	Abe M, <u>Kikuchi K</u> , et al	Current dialyzer classification in Japan and mortality risk in patients undergoing hemodialysis	Sci Rep	14(1)	doi: 10.1038/s41598-024-60831-y	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
137)	岩本淳一, 門馬匡邦, 玉虫惇, 上田元, 中川俊一郎, 森山由貴, 小西直樹, 屋良昭一郎, 宮崎照雄, 平山剛, 池上正, 本多彰.	長期経口摂取困難例および炎症性腸疾患でのカルニチン欠乏に関する検討	消化と吸収	47(1)	53	2024	
138)	宮崎照雄, 上田元, <u>池上正</u> , 本多彰.	胆汁酸によるタウリンの動態制御の雌雄差-胆汁酸ヒト化マウスを用いた検討	タウリンリサーチ	10(1)	8-12	2024	
139)	門馬匡邦, 岩本淳一, 玉虫惇, 上田元, 小西直樹, 屋良昭一郎, 宮崎照雄, 池上正, 本多彰.	血中胆汁酸分析を用いた dysbiosis の評価	消化と吸収	46(2)	155-8	2024	
140)	Ueda H, Honda A, Miyazaki T, Morishita Y, Hirayama T, Iwamoto J, <u>Ikegami T</u> .	High-fat/high-sucrose diet results in a high rate of MASH with HCC in a mouse model of human-like bile acid composition.	Hepatol Commun	9(1)	e0606	2024	○
141)	Sasaki K, Kawanaka M, Tomiyama Y, Takaki A, Otsuka M, Ikeda F, Yoshioka N, Kaneto H, Wada J, Fukuda T, Hino K, <u>Nishina S</u> .	Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma.	Hepatol Res			in press	○
142)	Miwa T, Hanai T, Hirata S, Nishimura K, Sahashi Y, Unome S, Imai K, Shirakami Y, Suetsugu A, Takai K, <u>Shimizu M</u> .	Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study.	Clin Nutr ESPEN	63	267-273	2024	○
143)	Miwa T, Hanai T, Hayashi I, Hirata S, Nishimura K, Unome S, Nakahata Y, Imai K, Shirakami Y, Suetsugu A, Takai K, <u>Shimizu M</u> .	Dysphagia risk evaluated by the Eating Assessment Tool-10 is associated with health-related quality of life in patients with chronic liver disease.	Nutrition	124	112440	2024	○
144)	Miwa T, Hanai T, Hirata S, Nishimura K, Unome S, Nakahata Y, Imai K, Shirakami Y, Suetsugu A, Takai K, <u>Shimizu M</u> .	Animal naming test stratifies the risk of falls and fall-related fractures in patients with cirrhosis.	Sci Rep	14	4307	2024	○
145)	Miwa T, Richardson JK, Murphy SL, Ellmers TJ, Miwa Y, Maeda T, Hanai T, <u>Shimizu M</u> .	Short-latency reaction time and accuracy are impaired in patients with cirrhosis: An international multicenter retrospective study.	Geriatr Gerontol Int	24	25-31	2024	○
146)	Miwa T, Utakata Y, Hanai T, Aiba M, Unome S, Imai K, Takai K, Shiraki M, Katsumura N, <u>Shimizu M</u> .	Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: Impact of amino acid imbalance.	J Gastroenterol	59	849-857	2024	○
147)	Hanai T, Nishimura K, Unome S, Miwa T, Nakahata Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u> .	Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.	J Gastroenterol	59	932-940	2024	○
148)	Hanai T, Nishimura K, Unome S, Miwa T, Nakahata Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u> .	Nutritional counseling improves mortality and prevents hepatic encephalopathy in patients with alcohol-associated liver disease.	Hepatol Res	54	1089-1098	2024	○
149)	Hanai T, Nishimura K, Unome S, Miwa T, Nakahata Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u> .	A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.	J Gastroenterol	59	45-55	2024	○
150)	Imai K, Takai K, Aiba M, Unome S, Miwa T, Hanai T, Suetsugu A, <u>Shimizu M</u> .	Adverse events in targeted therapy for unresectable hepatocellular carcinoma predict clinical outcomes.	Cancers	16	3150	2024	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
151)	Imai K, Takai K, Unome S, Miwa T, Hanai T, Suethugu A, <u>Shimizu M</u> .	Lenvatinib exacerbates the decrease in skeletal muscle mass in patients with hepatocellular carcinoma, whereas atezolizumab plus bevacizumab does not.	Cancers	16	442	2024	